Price and volume figures reflect the August 19, 2026 market snapshot at approximately 11:02 AM EDT;

Moderna Stock Is Having Its Biggest Day in Years

Moderna stock is the market’s biggest biotechnology story today after the company and Merck announced a major Phase 3 success for intismeran autogene, Moderna’s individualized mRNA-based cancer therapy, in combination with Merck’s KEYTRUDA.

At 11:02 AM EDT on August 19, MRNA was trading at $145.51, up $82.55, or 131.11%, after reaching an intraday high of $163.47. The stock opened a new trading regime after spending months near the $50–$70 range.

The move represents an extraordinary repricing of Moderna’s oncology opportunity. Reuters reported that Moderna shares more than doubled following the trial announcement, while Merck shares also climbed approximately 10% and the broader healthcare sector reached a record high.

Moderna Stock — August 19 Live Market Snapshot

The volume surge is particularly striking: 87.1 million shares versus an approximately 5.8 million 65-day average represents roughly 15 times normal trading activity.

🚨 The Catalyst: Moderna and Merck Hit a Phase 3 Cancer-Vaccine Milestone

The breakthrough centers on intismeran autogene, formerly known as mRNA-4157/V940, an individualized neoantigen therapy developed by Moderna in collaboration with Merck.

The therapy is designed using the unique mutation profile of a patient’s tumor. Moderna’s platform can encode up to 34 tumor-specific neoantigens, with the resulting mRNA therapy intended to stimulate a patient’s immune system against cancer-specific targets.

The Phase 3 INTerpath-001 trial evaluated intismeran plus KEYTRUDA versus KEYTRUDA alone in patients with completely resected, high-risk Stage II–IV melanoma. The trial was designed around recurrence-free survival (RFS), with distant metastasis-free survival (DMFS) as a key secondary endpoint.

What Moderna and Merck Reported

The companies announced that the combination:

• Met its primary endpoint of recurrence-free survival
• Produced a statistically significant and clinically meaningful improvement versus KEYTRUDA alone
• Met a key secondary endpoint for distant metastasis-free survival
• Produced no new safety signals compared with the established safety profile

Detailed efficacy figures from the Phase 3 readout were not yet publicly released as of the latest reporting. The companies said the data will be presented at an upcoming medical meeting and shared with regulatory authorities.

That distinction matters: the headline result is exceptionally positive, but investors do not yet have the complete Phase 3 dataset needed to assess the magnitude of benefit, long-term overall survival and full safety profile.

🧬 Why This Result Is So Important for Moderna

This isn’t simply another positive clinical-trial result.

Moderna has been trying to transform itself from a company heavily associated with COVID vaccines into a diversified biotechnology company with meaningful oncology and rare-disease revenues.

Its own shareholder materials previously identified intismeran as a potential cornerstone of this transition and said a positive Phase 3 result could support a potential launch as early as 2027.

Moderna has also been building the infrastructure needed for that transition. Its Marlborough facility was designed to manufacture intismeran at commercial scale, while the company reorganized its business in June around potential product launches in 2027 and 2028.

The oncology pipeline extends beyond melanoma.

Moderna and Merck have programs evaluating intismeran across non-small-cell lung cancer, bladder cancer, renal-cell carcinoma and other tumor types. Moderna reported nine Phase 2 and Phase 3 oncology studies involving intismeran across multiple cancer settings.

📈 The Earlier Phase 2 Data Already Suggested Something Big

Today’s Phase 3 result did not come out of nowhere.

The earlier randomized Phase 2b KEYNOTE-942 trial had already produced strong long-term data.

At a median follow-up of 60.3 months:

The Phase 2b study showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. The overall-survival analysis showed an encouraging trend but had a wide confidence interval and was exploratory.

Today’s Phase 3 confirmation therefore represents a major validation of a signal Moderna and Merck had already been following for several years.

💰 What the Breakthrough Could Mean for Moderna’s Revenue

Analysts are now reassessing Moderna’s long-term revenue potential.

Reuters reported that analysts see the melanoma vaccine potentially launching in 2027, with potential multibillion-dollar peak sales if development, regulatory approval and commercialization continue successfully.

MarketWatch cited potential annual sales of as much as approximately $2.5 billion for melanoma alone, although that remains an external estimate rather than company guidance.

The larger opportunity could be considerably broader if the technology succeeds in additional cancers.

The key distinction is that Moderna is no longer being valued only on its respiratory-vaccine franchise. Investors are beginning to price in the possibility of a multi-indication oncology platform.

💥 Why the Stock Move Is So Extreme

Moderna’s previous business was heavily influenced by COVID vaccine demand. Its recent financial results showed the pressure facing the existing commercial portfolio.

For Q2 2026, Moderna reported approximately $145 million in revenue, a GAAP net loss of approximately $0.8 billion, and GAAP EPS of −$1.97. The company nonetheless reiterated its plan to deliver up to 10% revenue growth in 2026 and improved its expected year-end cash balance to $4.7–$5.2 billion.

That makes today’s oncology result especially important.

The market is effectively asking:

Can intismeran become the product that replaces some of the revenue lost from Moderna’s COVID-era decline?

Today’s answer from investors appears to be an emphatic yes — although approval and commercialization risks remain.

🏆 Merck Stock Is Winning Too

Moderna is not the only beneficiary.

Merck’s KEYTRUDA is already one of the world’s largest oncology franchises. Combining KEYTRUDA with an individualized cancer vaccine creates a potential new treatment paradigm while potentially expanding the drug’s role in earlier-stage disease.

Merck shares rose roughly 9–11% during today’s trading, according to market reports.

The strategic significance is substantial because the partnership potentially extends KEYTRUDA into a new individualized neoantigen-therapy setting.

For Moderna, the upside is primarily platform validation and future oncology revenue.

For Merck, the upside includes potential expansion and lifecycle extension for KEYTRUDA.

📊 Moderna Stock Forecast: The Levels That Matter Tomorrow

Today’s move has created an entirely new technical structure.

There is no need to rely on old $50–$80 support levels after a move this large.

MRNA Technical Levels

The user-supplied 11:02 AM snapshot places the session high at $163.47 and low at $114.46.

The first major test for Tuesday is therefore whether MRNA can hold the $135–$140 area and eventually break $163.47.

A clean breakout above $163.47 could put $175 into focus, followed by the psychologically important $200 level.

A failure to hold the $135–$140 region would increase the probability of a retracement toward $114–$115.

These are technical scenarios, not analyst price targets.

🔮 Moderna Stock Forecast: Bull, Base and Bear Scenarios

The most important near-term risk is that today’s market reaction has moved far ahead of the detailed clinical dataset.

Reuters reported that analysts remain positive but cautious because overall-survival data, detailed safety results and manufacturing feasibility still need to be evaluated.

⚠️ What Could Stop Moderna’s Rally?

Despite today’s extraordinary result, several risks remain.

Regulatory risk: A successful Phase 3 trial does not automatically equal FDA or EMA approval.

Clinical-data risk: Detailed Phase 3 efficacy and safety data have not yet been released.

Manufacturing risk: Personalized cancer vaccines must be manufactured rapidly for individual patients, creating scalability and cost challenges.

Commercial risk: The eventual treatment must compete within an already established melanoma-treatment ecosystem.

Valuation risk: MRNA has already doubled or more in a single session. Even with a successful trial, profit-taking can be severe after such a rapid repricing.

🚀 What Investors Should Watch Next

The immediate catalyst is full Phase 3 data.

The next major milestones are:

1. Detailed INTerpath-001 results at an upcoming medical meeting.
2. Regulatory discussions and submissions with the FDA and other agencies.
3. Development progress in lung, bladder and kidney cancers.
4. Commercial manufacturing readiness for intismeran.
5. Potential launch preparation targeting 2027, assuming regulatory approval.

The 2027 timing should be viewed as a potential launch objective, not a guaranteed approval date. Moderna’s own earlier planning documents described a potential launch as early as 2027 if Phase 3 data were positive.

📌 Moderna Stock Today — The Numbers That Matter

The intraday high of $163.47 was independently reported by market coverage of today’s move.

Bottom Line: Moderna’s “Second Chapter” Has Arrived

Moderna stock’s 131% intraday surge represents much more than a typical biotech rally.

The Phase 3 INTerpath-001 result provides the strongest clinical validation yet for Moderna’s attempt to use individualized mRNA technology in cancer treatment. Earlier Phase 2 data had already demonstrated durable improvements in recurrence-free and distant metastasis-free survival; today’s Phase 3 success now moves that thesis into a far more commercially credible phase.

But the stock’s next move will depend on whether the clinical details, regulatory path and manufacturing economics justify the extraordinary valuation reset that occurred today.

For traders, $163.47 is the immediate breakout level, $135–$140 is the first support zone, and $114–$115 is the critical downside level from today’s opening volatility.

For long-term investors, the bigger question is even more important:

Can intismeran transform Moderna from a post-COVID vaccine company into a diversified oncology and mRNA biotechnology company?

Today’s market is clearly betting that the answer could be yes.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment or legal advice. Biotechnology investments carry substantial clinical, regulatory, manufacturing and commercial risks. Today’s Phase 3 result is a major positive development, but it does not guarantee FDA or other regulatory approval, commercial success or future stock performance. Intraday prices can change continuously. Support, resistance and scenario prices are technical reference levels, not guaranteed forecasts or investment recommendations. External sales projections are third-party estimates and do not represent Moderna guidance. Always complete independent due diligence before trading or investing.

About The Author

Kasia Davis

See author's posts